DexCom, Inc. $DXCM Shares Sold by Fisher Asset Management LLC

by · The Cerbat Gem

Fisher Asset Management LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 230,413 shares of the medical device company’s stock after selling 33,151 shares during the quarter. Fisher Asset Management LLC’s holdings in DexCom were worth $15,293,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of DXCM. Holocene Advisors LP acquired a new position in DexCom in the 3rd quarter worth about $163,964,000. CIBC Private Wealth Group LLC raised its holdings in DexCom by 374.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after purchasing an additional 2,294,709 shares during the period. Vanguard Group Inc. raised its holdings in DexCom by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares during the period. Intermede Investment Partners Ltd acquired a new position in DexCom in the 4th quarter worth about $60,351,000. Finally, Iron Triangle Partners LP acquired a new position in DexCom in the 3rd quarter worth about $57,196,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $70.26 on Thursday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The stock has a 50 day moving average of $63.95 and a two-hundred day moving average of $66.27. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market cap of $27.11 billion, a P/E ratio of 30.03, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the business earned $0.32 EPS. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DXCM. Bank of America reduced their price target on DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, March 24th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. Finally, Benchmark began coverage on DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.21.

View Our Latest Analysis on DexCom

Insider Activity

In other news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total value of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares of the company’s stock, valued at $6,560,384.64. This trade represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,871 shares of company stock worth $2,306,638 over the last ninety days. Corporate insiders own 0.28% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).